Apoptosis and tumorigenesis in human cholangiocarcinoma cells: Involvement of Fas/APO-1 (CD95) and calmodulin

American Journal of Pathology

Volumn 155, Issue 1, 1999, Pages 193-203

  Pan, George ^a   Vickers, Selwyn M ^b   Pickens, Allan ^b   Phillips, John O ^c   Ying, Weizhong ^c   Thompson, John A ^b   Siegal, Gene P ^a   McDonald, Jay M ^a,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c and Clinical Center   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; CALMODULIN INHIBITOR; FAS ANTIGEN; FULVESTRANT; TAMOXIFEN; TRIFLUOPERAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CARCINOMA CELL; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0032983453     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65113-9     Document Type: Article

References (71)

1. Perry RR, Kang Y, Greaves B: Effect of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995, 2:238-245
2. Kang Y, Cortina R, Perry RR: Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer. J Natl Cancer Inst 1996, 88:279-284
3. Frankfurt OS, Sugarbaker EV, Robb JA, Villa L: Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 1995, 97:149-154
4. Love RR: Tamoxifen therapy in primary breast cancer: biology, efficacy, side effects. J Clin Oncol 1989, 7:8013-8015
5. Butta A, Maclennan K, Flanders KC, Sacks NP, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Introduction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992, 52:4261-4264
6. Sampson LK, Vickers SM, Ying W, Phillips JO: Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res 1997, 57:1743-1749
7. Taylor OM, Benson EA, McMahon MJ: Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumor Group. Br J Surg 1993, 80:384-386
8. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosicky FT: Effects of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990, 50:7134-7138
9. Couldwell WT, Weiss MH, DiGiorgio LM, Weiner LP, Hinton DR, Ehsesmann LR, Corti PS, Apuzzo MLJ: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993, 32:485-490
10. Gelmann EP: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997, 24(suppl 1): S65-S70
11. Ward RL, Morgan G, Falley D, Kelly PJ: Tamoxifen reduces bone turnover and prevents lumbar spine proximal femoral bone loss in early postmenopausal women. Bone Miner 1993, 22:87-94
12. Recker RR: Clinical review 41: current therapy for osteoporosis. J Clin Endocrinol Metab 1993, 76:14-16
13. Grainger DJ, Witchell CM, Metcalfe JC: Tamoxifen elevates transforming growth factor-β suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1995, 1:1067-1073
14. Reckless J, Metcalfe JC, Grainger DJ: Tamoxifen decreases cholesterol seven-fold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997, 95:1542-1548
15. Sthoeger Z, Dayan M, Zinger H, Kalush F, Mor G, Zlatman YA, Kohen F, Mozes E: Treatments with tamoxifen and an antiestradiol antibody have beneficial effects on experimental SLE via cytokine modulation. Ann N Y Acad Sci 1997, 815:367-368
16. Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltzman Y, Kohen F, Sthoeger Z, Mozes E: The beneficial effects of treatment with tamoxifen and anti-estradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 1997, 90:101-108
17. Grainger DJ, Metcalfe JC: Tamoxifen: teaching an old drug new tricks. Nat Med 1996, 2:381-385
18. Santambrogio L, Hochwald GM, Saxene B, Len CH, Martz JE, Carlino JA, Ruddle NH, Paladino MA, Gold LI, Thorbecke GJ: Studies on the mechanisms by which transforming growth factor-β protects against allergic encephalomyelitis-antagonism between TGF-β and tumor necrosis factor. J Immunol 1993, 151:1116-1127
19. Benson JR, Baum M: Modulation of transforming growth factor β expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells. Br J Cancer 1995, 72:1441-1446
20. Pierce DF, Gorska Jr AE, Chytil A, Meise KS, Page DL, Coffey RJ, Moses Jr HL: Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc Natl Acad Sci USA 1995, 92: 4254-4258
21. Stein B, Yang MX: Repression of the interleukine-6 promoter by estrogen receptor is mediated by NFκB and C/EBPB. Mol Cell Biol 1995, 15:4971-4979
22. Lopes MCF, Vale MGP, Carvalho AP: Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res 1990, 50:2753-2758
23. MacNeil S, Dawson RA, Cracker G, Tucker WF, Bittiner B, Singleton JG, Hunter T, Tierney DF: Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity. Br J Dermatol 1993, 128:143-150
24. Nilius B, Prenen J, Szucs G, Wei L, Tanzi F, Voets T, Droogmans G: Calcium-acitated chloride channels in bovine pulmonary artery endothelial cells. J Physiol 1997, 498:381-396
25. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 1985, 45:2462-2465
26. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 169:1747-1756
27. Trauth BC, Klas C, Peter AMJ, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305
28. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
29. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, LiWever M, Richards S, Dhein J, Trauth BC, Ponstingl H, Krammer PH: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992, 267:10709-10715
30. Itoh N, Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993, 268: 10932-10937
31. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV: A novel domain within the 55 kDa TNF receptor signals cell death. Cell 1993, 74:845-853
32. Watanabe-Fukenaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen. J Immunol 1992, 125:871-876
33. Watanabe-Fukenaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorders in mice explained by defects in Fas antigen that mediated apoptosis. Nature 1992, 356:314-317
34. Wu JX: Apoptosis and antiogenesis: two promising tumor markers in breast cancer. Anticancer Res 1996, 16:2233-2240
35. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462
36. Trauth BC, Klas C, Peter AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305
37. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH: Induction of apoptosis by monoclonal anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992, 149:3166-3173
38. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993, 69:415-429
39. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996, 56:3870-3874
40. Wang GHW, Goeddel DV: Fas antigen and p55 TNF receptor signal apoptosis through distinct pathway. J Immunol 1994, 152:1751-1755
41. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762
42. Owen-Schaub LB, Radinsky R. Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological response. Cancer Res 1994, 54:1580-1586
43. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997, 3:294-300
44. Debatin KM, Beltinger C, Bohler T, Fellenberg J, Friesen C, Fulda S, Herr I, Los M, Scheuerpflug C, Sieverts H, Stahnke K: Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Biochem Soc Trans 1997, 25:405-410
45. Radding W, Pan ZQ, Hunter E, Johnston P, Williams JP, McDonald JM: Expression of HIV-1 envelope glycoprotein alters cellular calmodulin. Biochem Biophys Res Commun 1996, 218:192-197
46. Pan ZQ, Radding W, Zhou T, Hunter E, Mountz JD, McDonald JM: Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Am J Pathol 1996, 149:903-910
47. + T-cells from patients with AIDS. Immunopharmacol 1998, 40:91-103
48. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, Kloppel G, Lemoine NR: Loss of membrane E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994, 174:243-248
49. Janckwski JA, Newham PM, Kemic O, Hirano S, Takeichi M, Pignatelli M: Differential expression of E-cadherin in normal, metaplastic and dysplastic oesophageal mucosa: a purative biomarker. Int J Oncol 1994, 4:441-448
50. Taoka H, Kawarada Y: Intrahepatic bile duct carcinoma (cholangiocarcinoma). J Jpn Surg Soc 1997, 98:484-490
51. Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen CL: Surgical treatment of cholangiocarcinoma. Hepato-Gastroenterol 1997, 44:760-765
52. Leung JT, Kuan R: Intraluminal brachytherapy in the treatment of bile duct carcinomas. Australas Radiol 1997, 41:151-154
53. Kawamura K, Grabowski D, Krivacic K, Hidaka H, Ganapathi R: Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes: role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem Pharmacol 1996, 52:1903-1909
54. Nagata S, Golstein P: The Fas death factor. Science 1995, 267:1449-1456
55. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MS, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 1994, 345:43-46
56. Kang Y, Cortina R, Perry RR: Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 1996, 88:279-284
57. Perry RR, Kang Y, Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent -independenl human breast cancer cells. Ann Surg Oncol 1995, 2:238-245
58. Vertosick Jr FT, Selker RG, Rall MS, Kristofik MP, Rehn T: A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol 1994, 19:97-103
59. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A: DAP kinase links the control of apoptosis to metastasis. Nature 1997, 390:180-184
60. Maeda S, Suzuki A, Lin KH, Inagaki H, Saito T: DNA fragmentation induced in high-cell-density culture of primary rat hepatocytes is an active process dependent on energy availability, gene expression, and calmodulin. J Biochem 1995, 118:161-1165
61. McConkey DJ, Orrenius S: Breakthrough views: the role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 1997, 239:357-366
62. Baffy G, Miyashita T, Williamson JR, Reed JC: Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced BCL-2 oncoprotein production. J Biol Chem 1993, 268:6511-6519
63. Squier MKT, Miller ACK, Malkinson AM, Cohen JJ: Calpain activation in apoptosis. J Cell Physiol 1994, 159:229-237
64. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA: Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996, 15:3835-3844
65. Melino G, Annicchiarico-Petruzzeli M, Piredda L, Candi E, Gentile V, Davies PJ, Piacentini M: Tissue transglutaminase apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994, 14:6584-6596
66. Catherino WH, Jordan VC: A risk-benefit assessment of tamoxifen therapy. Drug Saf 1993, 8:381-397
67. Millward MJ, Lien EA, Robinson A, Cantwell BMJ: High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 1994, 51:79-83
68. Martinez-Lorenzo MJ, Alava MA, Anel A, Naval J: Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996, 89:511-517
69. Mori T, Xu JP, Mori E, Sato E, Saito S, Guo MW: Expression of Fas-Fas ligand system associated with atresia through apoptosis in murine ovary. Horm Res 1997, 48(suppl 3):11-19
70. Wilson SE, Li Q, Weng J, Barry-Lane PA, Jester JV, Liang Q, Wordinger RJ: The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci 1996, 37:1582-1592
71. Martinez-Lorenzo MJ, Alava MA, Anel A, Pineiro A, Naval J: Release of performed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996, 89:511-517